Intermediate-Timed Alemtuzumab May be Associated with Increased Graft Rejection in Reduced-Intensity Bone Marrow Transplant for Sickle Cell Disease Read more about Intermediate-Timed Alemtuzumab May be Associated with Increased Graft Rejection in Reduced-Intensity Bone Marrow Transplant for Sickle Cell Disease